• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

Treatment discontinuation in MS: the DOT-MS trial

May 5, 2025  

CLINICAL CASES IN MS: A 24 Y.O. WOMAN WITH PARESTHESIAE AND NON-ENHANCING LESIONS

April 25, 2025  

AAN 2025 – report on fluid biomarkers in MS

April 22, 2025  

Ofatumumab – new data on efficacy and safety

April 14, 2025  

AAN DAILY HIGHLIGHTS – WEDNESDAY, APRIL 9, 2025

April 9, 2025  

AAN DAILY HIGHLIGHTS – TUESDAY, APRIL 8, 2025

April 8, 2025  

AAN DAILY HIGHLIGHTS – MONDAY, APRIL 7, 2025

April 7, 2025  

ACTRIMS Forum 2025 highlights – Update on ocrelizumab

March 24, 2025  

ACTRIMS Forum 2025: Update on biomarkers

March 17, 2025  

CLINICAL CASES IN MS: A PATIENT WITH WORSENING FATIGUE AND NEW MOBILITY PROBLEMS

March 13, 2025  
1
2
3
Next

Browse by Topic

  • EPILEPSY (36)
  • MS (412)
  • CLINICAL CASES IN MS (15)
  • BIOMARKERS IN MS (54)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • Library (17)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • McDonald criteria 2024: what changes can we expect? posted on January 30, 2024
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • CNS effects of Wegovy (semaglutide) posted on February 28, 2023
Copyright 2025 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions